-
December 20, 2012
Novo Nordisk (NVO) recently completed a phase IIIa study on IDegLira, which is a combination of Tresiba (insulin ...
-
December 20, 2012
Talks between Democrats and Republicans on the Fiscal Cliff issue took a negative turn, dragging the benchmarks into ...
-
December 19, 2012
Boston Scientific Corporation (BSX) recently commenced a trial for its next-generation Ingevity pacing leads. The ...
-
December 19, 2012
Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. ...
-
December 19, 2012
Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) ...
-
December 18, 2012
GlaxoSmithKline (GSK) recently announced that its inhalational anthrax candidate, raxibacumab, has received US Food ...
-
December 17, 2012
Insulet Corporation (PODD), a leading tubeless insulin pump maker, has won 510(k) Food and Drug Administration (FDA) ...
-
December 17, 2012
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not ...
-
December 17, 2012
The US Food and Drug Administration ("FDA") recently approved Novartis' (NVS) Signifor (pasireotide) to treat adults ...
-
December 17, 2012
Eli Lilly and Company (LLY) recently announced its decision to scrap one of three pivotal phase III studies being ...
-
December 14, 2012
Janssen Research & Development, LLC, a part of the Johnson & Johnson (JNJ) family of companies, recently announced ...
-
December 13, 2012
Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, has ...
-
December 13, 2012
Sanofi (SNY) recently announced positive results from a phase II trial evaluating the efficacy of its hematology ...
-
December 13, 2012
Eli Lilly (LLY) recently provided an update on its plans for its Alzheimer's disease candidate, solanezumab. The ...
-
December 12, 2012
Johnson & Johnson's (JNJ) Janssen recently announced that the FDA has granted approval for the label expansion of ...
-
December 11, 2012
Recently, the board of directors at Gilead Sciences Inc. (GILD) authorized a two-for-one stock split. The action, ...
-
December 11, 2012
Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently ...
-
December 10, 2012
Merck (MRK) recently moved its Alzheimer's disease candidate, MK-8931, into a phase II/III study (EPOCH). The study ...
-
December 10, 2012
Vertex Pharmaceuticals Incorporated (VRTX) recently announced the approval of its cystic fibrosis (CF) treatment, ...
-
December 07, 2012
Investors were left disappointed when Align Technologies (ALGN), a major player in the malocclusion market, ...
